- Home
- FTHM vs PLUR Comparison
FTHM vs PLUR Comparison
Compare FTHM & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | PLUR |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 25.5M |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | FTHM | PLUR |
|---|---|---|
| Price | $0.86 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 296.1K | 43.7K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,477,000.00 | $1,336,000.00 |
| Revenue This Year | $11.67 | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.45 | ★ 309.82 |
| 52 Week Low | $0.40 | $1.56 |
| 52 Week High | $3.37 | $5.68 |
Technical Indicators
Market Signals| Indicator | FTHM | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 38.86 |
| Support Level | $0.85 | $1.56 |
| Resistance Level | $1.07 | $2.50 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 26.84 | 31.61 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.